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ABSTRACS 
The binding of losartan potassium, an angiotensin II receptor antagonist, to bovine serum albumin was 
studied by equilibrium dialysis method (ED) in presence or absence of palmitic acid. The study was 
carried out using ranitidine and diazepam as site-1 and site-2 specific probe, respectively. Different 
analysis of binding of losartan to bovine serum albumin suggested two sets of association constants: 
high affinity association constant (k1 = 11.2 x 105 M-1) with low capacity (n1 = 2) and low affinity 
association (k2 = 2. 63 x 105 M-1) constant with high capacity (n2 = 10) at pH 7.4 and 27°C. During 
concurrent administration of palmitic acid and losartan potassium in presence or absence of ranitidine 
or diazepam, it was that found that palmitic acid causes the release of losartan potassium from its 
binding site on BSA resulting reduced binding of losartan potassium to BSA. The increment in free 
fraction of losartan potassium was from 13.1% to 47.2 % upon the addition of increased concentration 
of only palmitic acid at a concentration of 0 x 10-5 M to 16 x 10-5 M. In presence of ranitidine or 
diazepam as site specific probes, palmitic acid further increases the free fraction of losartan potassium 
were from 22.8% to 53.4% and 35.3 to 65.5%, respectively. This data provided the evidence of 
interaction of higher concentration of palmitic acid at the binding sites on BSA changing the 
pharmacokinetics properties of losartan potassium. 
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INTRODUCTION 
Serum albumin, the most abundant protein in blood plasma serves as a depot and transport 
protein for numerous endogenous and exogenous compounds
1. The most outstanding property 
of albumin is its ability to bind reversibly an incredible variety of ligands including fatty 
acids, amino acids (tryptophan and cysteine), steroids, metals such as calcium, copper and 
zinc, and numerous pharmaceuticals 
2. 
On the basis of probe displacement method, it has been found that there are at least three 
relatively high specific drug binding sites on the HAS molecule. These sites are commonly FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    29 
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called the warfarin/ranitidine, the benzodiazepine and the digoxin binding sites, and are also 
denoted as site I, site II and site III, respectively
3,4. Site II or benzodiazepine binding site is 
more specific than site I. Most drugs bind with proteins by a reversible process. Plasma 
protein binding properties are primarily determinants of the pharmacokinetic properties of 
most of the drugs, such as plasma clearance, half-life, apparent volume of distribution and the 
duration and intensity of pharmacologic effect
5. Drug displacement also affects other aspects 
of drug deposition, such as, metabolism and excretion 
6. 
Free fatty acids are highly protein bound and replace many drugs and other ligands from 
its’ binding site on albumin 
7-9. Goodman 
10 concluded that the two sites in the first binding 
class of fatty acids (laurate, myristate, palmitate, stearate, oleate and linoleate), in contrast to 
the sites in the second binding class, are “rather specifically constructed”. The specified of the 
high affinity sites of long-chain fatty acids was supported by some authors 
11. Other binding 
studies indicate that the high affinity binding sites of short and medium-chain fatty acids 
probably also are placed in other regions on the albumin molecule 
7. 
Losartan Potassium, an angiotensin II receptor antagonist and commonly prescribed for the 
management of hypertension. A recent study shows that losartan potassium highly protein 
bound and suprapharmacologic concentrations of the NSAIDs increased the free fraction of 
losartan 
13. However, until now, no report has been published relating the interference of free 
plasma fatty acid in the binding profile of losartan potassium. Consumption of high fat diet 
sharply increases the free fatty acid levels in blood. Since fatty acids are highly protein bound, 
therefore, we hypothesize that high dietary fat originated free fatty acid may displace many 
drugs from its binding sites on albumin and may affect the pharmacokinetic properties of the 
drugs. Therefore, the present study was undertaken to characterize the binding profile of 
losartan potassium as well as to notify the interaction of palmitic acid with losartan potassium 
at its binding site on albumin using bovine serum albumin employing equilibrium dialysis 
methods. 
MATERIAL AND METHODS 
Materials and instruments 
Dialysis membrane (molecular cut off 3500 daltons) and bovine serum albumin (fatty acid 
free, fraction V, 96-98%) used in the experiment were purchased from Medicell International 
Ltd., UK and Sigma Chemical Co., USA, respectively. Losartan potassium, ranitidine 
hydrochloride and diazepam were kind gift from a local pharmaceutical company of 
Bangladesh. Disodium hydrogen phosphate (Na2HPO4), potassium dihydrogen phosphate 
(KH2PO4), palmitic acid and borax (NaB4O7.H2O) were obtained from Sigma., USA. High-
resolution UV-VIS spectrophotomer (UV-1800, Shimadzu, Japan) and Metabolic Shaking 
Incubator (Clifton Shaking Bath, Nickel Electro Ltd., England.) were used in the experiment. 
All other chemicals used in the experiment were commercial grade. Equilibrium Dialysis 
method was employed in this study 
14,15. Dialysis membrane used in the experiment was cut 
into small pieces and was boiled for 8 hours at 65-70 °C in de-ionized water to remove sulfur. FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    30 
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Preparation of Standard Curve 
For the preparation of standard curves of ranitidine hydrochloride, diazepam and losartan 
potassium, solutions of different concentrations (0×10
-5 M to 20×10
-5 M) of these drugs were 
prepared in phosphate buffer of 7.4 and taking absorbance values at determined λ max 318 nm, 
235 nm and 273 nm respectively. Standard curves were obtained by plotting the absorbance 
values against the corresponding the concentrations. 
Estimation of association constant  
To determine the association constant of losartan potassium, different concentrations 
(2×10
-5 M to 20×10
-5 M) of losartan potassium solutions were mixed with prepared BSA 
solution (2×10
-5 M in phosphate buffered saline, pH 7.4) to get a final volume of 5 ml each. 
These solutions were allowed to stand for sometime for the maximum binding of losartan 
potassium to BSA. From each mixture, 3.5 ml of solution was withdrawn poured into 
previously prepared semi-permeable membrane tubes and both sides of the membranes were 
sealed properly as there was no leakage. The membrane tubes containing drug-protein 
mixture were immersed in conical flasks containing 30 ml of phosphate buffer (pH 7.4) and 
were placed in a metabolic shaker for dialysis for 12 hours (27 °C, 20 rpm). Buffer samples 
were collected from each conical flask after dialysis and free fraction of losartan potassium 
was measured by UV spectrophotometer (λ max 273 nm).  
Determination of binding site of losartan potassium using ranitidine as site-I specific 
probe 
To determine the binding sites of losartan potassium at BSA, the concentrations of BSA 
and probe (ranitidine hydrochloride as site-I specific probe) were remained fixed in 1:1 ratio 
(2×10
-5 M: 2×10
-5 M) and the concentration of losartan potassium was added in increased 
concentration (0
 to 16×10
-5 M). So, the final ratio of BSA: Probe: losartan  potassium were 
1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:5, 1:1:6, 1:1:8. The dialysis was carried out as described above 
and free fraction of ranitidine hydrochloride was measured at λ  max  318 nm. Only BSA 
solution and mixture of BSA and losartan potassium were used positive and negative control 
during the measurement. Alternatively, BSA and losartan potassium were mixed in 1:1 ratio 
(2×10
-5 M: 2×10
-5 M) and ranitidine hydrochloride was added in increasing concentration (0
  
to 16×10
-5 M) and the final ratio of BSA: Drug: Probe were 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:5, 
1:1:6, 1:1:8. The dialysis was carried out as described above and free fraction of losartan 
potassium was measured at λ max 204 nm. As describe above, negative and positive control 
were maintained during the measurement. 
Determination of binding site of losartan potassium using diazepam as site-II specific 
probe 
The binding sites of losartan potassium at BSA, using diazepam as site-II specific probe, 
were determined employing the same methods as describe above. Briefly, BSA: diazepam: FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    31 
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losartan potassium were mixed at 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:5, 1:1:6, 1:1:8. The dialysis 
was carried out as described above and free concentration of diazepam was measured at λ max 
235 nm. Alternatively, BSA: losartan: diazepam were taken as 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:5, 
1:1:6, 1:1:8. After dialysis, free concentration of losartan potassium was measured at λ  max 
204 nm. Negative and positive controls were maintained in both cases of measurements. 
Effect of palmitic acid on losartan potassium bound to BSA 
The effect of palmitic acid on losartan potassium, when bound to BSA was estimated in 
absence and in presence of site specific probes using ranitidine as site-I specific and diazepam 
as site-II specific probes, respectively. In absence of site specific probes, the BSA and 
losartan potassium was mixed at 1:1 ratio (2 x10
-5 M: 2 x 10
-5 M) and then palmitic acid was 
added in increasing concentration (0 to 16 x 10
-5 M) to make final ratio of BSA, losartan and 
palmitic acid in each experiment as 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:6, 1:1:8 and 1:1:10. While in 
presence of probes; BSA, probe and losartan potassium were mixed at ratio of 1:2:1 and 
palmitic acid was added in increasing concentration to make the final ration of protein, probe, 
losartan and palmitic acid as 1:2:1:0, 1:2:1:1, 1:2:1:2, 1:2:1:4, 1:2:1:6, 1:2:1:8 and 1:2:1:10. 
Dialysis was carried out and the amount of free losartan potassium was measured in absence 
and in presence of probes as described above. Only BSA was used as positive control, 
mixture of BSA and palmitic acid, and mixture of BSA, palmitic acid and probe were used as 
negative control. 
RESULTS 
Estimation of binding parameters 
The binding parameters of losartan potassium have been characterized using Scatchard 
type of analyses of the binding of drug to albumin (Figure 1). Scatchard analysis of the 
binding of the drug at pH 7.4 and at 27
°  C provided a non-liner curve, suggesting the 
presence of at least two classes of binding sites for the binding of losartan potassium to BSA. 
As shown in Figure 1, the number of high affinity binding site (n1) for losartan was 
approximately two (low capacity) and the number of low affinity binding site (n2) was 
approximately 10 (high capacity). The high affinity association constant (kl) for the 
losartan binding to BSA at pH 7.4 is quite high (11.2 x 10
5 M
-1), while the low affinity 
association constant (k2) for this drug to BSA is about 4 fold lower (2.63 x 10
5 M
-1)
 than that 
of primary association constant. These findings indicate that losartan are highly bound to BSA.  
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Figure l. 
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Scatchard plot for the binding of Losartan potassium to BSA at p
H 7.4 and 27 
°C. Losartan potassium [0 x 10
-5 M to 
20 x 10
-5 M] was added to BSA [2 x 10
-5 M] and dialyzed as described under materials and methods. Free fraction 
of losartan was measured by UV-spectroscopic method and analyzed. 
Interaction of losartan potassium with site specific probes 
The effects of losartan potassium on the binding of site specific probes were examined to 
determine whether losartan potassium binds preferentially with site-I or site-II on BSA.As 
mentioned under materials and methods, site specific probe and BSA were mixed at 1:1 molar 
ratio and losartan potassium was added in an increased concentration from 0 x 10
-5 M to 16 x 
10
-5 M. The results showed that losartan potassium cause the increment of free fraction of 
ranitidine and diazepam from 16.6% to 35.7% and 11.5% to 47.3%, respectively (Figure 2). 
Figure 2. 
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Free fraction of ranitidine ( ) or diazepam () bound to BSA (1:1) upon the addition of losartan potassium at 
27
°C and pH 7.4. The concentrations used in the binding study were: [BSA] = [ranitidine] = 2×10
-5 M; 
[BSA] = [diazepam] = 2×10
-5 M; and [Losartan] = 0-16 ×10
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Interaction of palmitic acid with site specific probes 
The effect of palmitic acid was measured to know whether it can release the ranitidine and 
diazepam from their binding sites or not. It was found that palmitic acid at a concentration 
from 0 x 10
-5 M to 16 x 10
-5 M increased the free fraction ranitidine from 16.0 to 39.8% and 
of diazepam from 11.5% to 58.7% (Figure 3). 
Figure 3.  
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Free fraction of ranitidine ( ) or diazepam () bound to BSA (1:1) upon the addition of palmitic acid at 27
°C 
and pH 7.4. The concentrations used in the binding study were: [BSA] = [ranitidine] = 2×10
-5 M; [BSA] = 
[diazepam] = 2×10
-5 M; and [Losartan] = 0-16 ×10
-5 M. 
Interaction of palmitic acid with Losartan potassium at the binding sites on BSA  
Figure 4: 
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Palmitic acid (x 10
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Free fraction of losartan potassium in the absence or presence of ranitidine as site I specific probe to BSA at 2:1 
molar ratio upon the addition of palmitic acid at 27 
°C and pH 7.4. The molar concentrations used in the FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    34 
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binding study were: [BSA]:[probe]:[losartan] = 1:2:1; and [palmitic acid] = 0-16 ×10
-5 M. 
 
Figure 5:  
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Free fraction of losartan potassium in the absence or presence of diazepam as site II specific probe to BSA at 
2:1 molar ratio upon the addition of palmitic acid at 27 
°C and pH 7.4. The molar concentrations used in the 
binding study were: [BSA]:[probe]:[losartan] = 1:2:1; and [palmitic acid] = 0-16 ×10
-5 M. 
The interactions at bindings sites on BSA were measured between losartan potassium and 
palmtic acid in the absence or in presence of site specific probes ranitidine and diazepam, 
respectively. In absence of both ranitidine and diazepam, palmitic acid increased the free 
fraction of losartan potassium from 13.1% to  47.2% with the addition of palmitic acid from 0 
x 10
-5 M  to 16 x 10
-5 M (Figure 4 and 5). Whereas, in presence of ranitidine and diazepam as 
site specific probes, palmitic acid at the same concentration, incremented the free fraction of 
losartan potassium from 23.0% to 53.5% and 35.6% to 65.5%, respectively.  
DISCUSSION 
Binding of drugs are determined by studying its ability to displace the site specific 
probes. In this study ranitidine hydrochloride and diazepam were used as site-I and site-II 
specific probes, respectively. The association constants as shown in Table 1 indicate that 
losartan potassium is highly bound to BSA. Figure 2 shows the change in free 
concentration of ranitidine and diazepam by losartan. It is seen that the free concentration of 
ranitidine increased from 16.6% to 35.7%, whereas, the free concentration of diazepam 
was increased from 11.5% to 47.3% by the same drug. From this observation it can be said 
that losartan potassium at higher concentration displaced diazepam to a greater 
extent as compared to ranitidine, so losartan has greater affinity for site II than for site I 
on the BSA molecule. This implies the fact that at a lower drug to BSA ratio, losartan 
binds to its high affinity site i.e., site II or the benzodiazepine site, whereas at higher ratio 
it not only binds to its high affinity site but also to its low affinity site i.e., site I or the 
warfarin site on the BSA molecule. FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    35 
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Table 1: Association constant of Losartan potassium bound to BSA at pH 7.4 (27 
oC) 
  Association constant 
p
H 
k1 
(high affinity) 
×10
5M
-1 
k2 
(low affinity) 
×10
5M
-1 
7.4  11.2 ± 0.07  2.6 ± 0.03 
Note: Value represents the mean ± SEM of three independent experiments 
 
The pharmacokinetic properties of drugs are influenced by exogenous as well as 
endogenous compounds by binding to serum albumin in a reversible manner. Regular diet 
contains various fats and fatty acids. These fatty acids are highly protein bound and displaces 
drugs and other endogenous molecules from their binding sites on albumin [10-12]. Here we, 
for the first time, reported the in vitro interaction of palmitic acid with losartan potassium at 
the binding sites on BSA. Plasma protein binding properties are considered to be the primary 
determinants of the pharmacokinetic properties of many drugs. Therefore any alteration or 
change in the serum albumin binding of these drugs might lead to a change in the 
pharmacokinetic properties of these drugs. Figures 4 and 5 showed the change in the free 
concentration of losartan potassium bound to BSA in the presence of palmitic acid at pH 7.4 
and at 27ºC. As observed in Figure 4, the free fraction of losartan potassium bound to BSA  
was increased from 13.1% to 47.2% by palmitic acid in the absence of ranitidine, a site I 
specific probe. Whereas in the presence of ranitidine, this increment was from 23.0% to 
53.5%. While siteII was blocked by sufficient amount of diazepam, palmitic acid increased 
the free fraction of losartan potassium from 35.6% to 65.5% as shown in Figure 5. These 
findings do not contradict with the number of high and low affinity binding sites of losartan 
potassium on BSA. When site II was blocked by diazepam, initial free fraction was naturally 
at an elevated level because the number of low affinity binding sites of losartan potassium on 
BSA was 10 (this means that 10 molecules of losartan potassium bind to site-II on one 
molecule of BSA). This suggests that losartan potassium is displaced to a greater extent by 
palmitic acid in the presence of diazepam compared to ranitidine. 
CONCLUSION 
Serum binding can be one of the determinants for the pharmacokinetics of drugs. The aim 
of the study was to observe the effects of fatty acid on the binding of losartan potassium, an 
antihypertensive drugs, to BSA. Interaction at the binding site was also carried out during 
concurrent addition of fatty acid, Palmitic acid. We found that palmitic acid, a saturated fatty 
acid, displaces losartan potassium from its binding sites on BSA. As there is strong analogy 
between BSA and HSA, it is assumed that similar types of binding characteristics will be 
exhibited by losartan when bound to HSA. Sometimes the pharmacologic activity of a drug is 
related to its protein binding. If a drug shows less affinity for albumin due to any alteration in 
protein binding, the pharmacologic effect of the drug may be significantly altered. However, 
the results of the present study in combination with the current advances in the binding of 
losartan potassium and interaction with fatty acid might be helpful in realizing to the overall 
binding behavior of the drug with HSA. However, from our limited data it is too early to draw 
such conclusion about the pharmacokinetic/ pharmacological properties of the drug. It FERDOSI KABIR A. Interaction of Palmitic Acid with Losartan Potassium …    36 
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deserves a more detailed study using in vivo experimental model.  
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